ArticleNeurology2021
Clinical Correlation of Multiple Sclerosis Immunopathologic Subtypes.
Open access · greenAbstract read
In one paragraph
Article in Neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- A focus on the normal-appearing white and gray matter within the multiple sclerosis brain: a link to smoldering progression.Acta neuropathologica · 2025Review
- Kappa Free Light Chain Index Correlates With Prognostic Biomarkers in Multiple Sclerosis and Decreases Slowly Following Treatment.European journal of neurology · 2025Article
- NEK2 regulates B cell function and the severity of experimental autoimmune encephalomyelitis.Journal of neuroinflammation · 2025Article
- Differentiation of hemispheric white matter lesions in migraine and multiple sclerosis with similar radiological features using advanced MRI.Frontiers in neuroscience · 2024Article
- Defining the natural history of tumefactive demyelination: A retrospective cohort of 257 patients.Annals of clinical and translational neurology · 2023Article
- Microglia subtypes in acute, subacute, and chronic multiple sclerosis.Journal of neuropathology and experimental neurology · 2023Article
- Spinal cord and brain corticospinal tract lesions are associated with motor progression in tumefactive multiple sclerosis.Multiple sclerosis and related disorders · 2023Article
- Long-term clinical, imaging and cognitive outcomes association with MS immunopathology.Annals of clinical and translational neurology · 2023Observational
- Pathogenic role of autoantibodies at the ependyma in autoimmune disorders of the central nervous system.Frontiers in cellular neuroscience · 2023Article
- Remyelination in Multiple Sclerosis: Findings in the Cuprizone Model.International journal of molecular sciences · 2022Review
- Pathogenic autoantibodies in multiple sclerosis - from a simple idea to a complex concept.Nature reviews. Neurology · 2022Review
- Motor Behavioral Deficits in the Cuprizone Model: Validity of the Rotarod Test Paradigm.International journal of molecular sciences · 2022Review
- The contribution of neuropathology to multiple sclerosis research.European journal of neurology · 2022Review
- Population-based incidence and clinico-radiological characteristics of tumefactive demyelination in Olmsted County, Minnesota, United States.European journal of neurology · 2022Article
- Ponesimod in the Treatment of Relapsing Forms of Multiple Sclerosis: An Update on the Emerging Clinical Data.Degenerative neurological and neuromuscular disease · 2022Review
- The Potential for EBV Vaccines to Prevent Multiple Sclerosis.Frontiers in neurology · 2022Article
- Tissue donations for multiple sclerosis research: current state and suggestions for improvement.Brain communications · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 3 countries.
W Oliver TobinFrom the Department of Neurology (W.O.T., Y.G., L.L.), Health Sciences Research (S.D.W., N.T.), and Department of Pathology (J.E.P.), Mayo Clinic, Rochester, MN; Poznan University of Medical Sciences (A.K.-L.), Poland; University of Göttingen (I.M., W.B.), Germany; Medical University of Vienna (J.M.F., H.L.), Austria; and Departments of Neurosciences (C.F.L.), Neurology (C.F.L.), and Clinical and Translational Science (C.F.L.), Mayo Clinic, College of Medicine, Rochester, MN.ORCID 0000-0002-8141-2394
Alicja Kalinowska-LyszczarzFrom the Department of Neurology (W.O.T., Y.G., L.L.), Health Sciences Research (S.D.W., N.T.), and Department of Pathology (J.E.P.), Mayo Clinic, Rochester, MN; Poznan University of Medical Sciences (A.K.-L.), Poland; University of Göttingen (I.M., W.B.), Germany; Medical University of Vienna (J.M.F., H.L.), Austria; and Departments of Neurosciences (C.F.L.), Neurology (C.F.L.), and Clinical and Translational Science (C.F.L.), Mayo Clinic, College of Medicine, Rochester, MN.ORCID 0000-0002-0618-1637
Stephen D WeigandFrom the Department of Neurology (W.O.T., Y.G., L.L.), Health Sciences Research (S.D.W., N.T.), and Department of Pathology (J.E.P.), Mayo Clinic, Rochester, MN; Poznan University of Medical Sciences (A.K.-L.), Poland; University of Göttingen (I.M., W.B.), Germany; Medical University of Vienna (J.M.F., H.L.), Austria; and Departments of Neurosciences (C.F.L.), Neurology (C.F.L.), and Clinical and Translational Science (C.F.L.), Mayo Clinic, College of Medicine, Rochester, MN.
Yong GuoFrom the Department of Neurology (W.O.T., Y.G., L.L.), Health Sciences Research (S.D.W., N.T.), and Department of Pathology (J.E.P.), Mayo Clinic, Rochester, MN; Poznan University of Medical Sciences (A.K.-L.), Poland; University of Göttingen (I.M., W.B.), Germany; Medical University of Vienna (J.M.F., H.L.), Austria; and Departments of Neurosciences (C.F.L.), Neurology (C.F.L.), and Clinical and Translational Science (C.F.L.), Mayo Clinic, College of Medicine, Rochester, MN.
Nirubol TosakulwongFrom the Department of Neurology (W.O.T., Y.G., L.L.), Health Sciences Research (S.D.W., N.T.), and Department of Pathology (J.E.P.), Mayo Clinic, Rochester, MN; Poznan University of Medical Sciences (A.K.-L.), Poland; University of Göttingen (I.M., W.B.), Germany; Medical University of Vienna (J.M.F., H.L.), Austria; and Departments of Neurosciences (C.F.L.), Neurology (C.F.L.), and Clinical and Translational Science (C.F.L.), Mayo Clinic, College of Medicine, Rochester, MN.
Joseph E ParisiFrom the Department of Neurology (W.O.T., Y.G., L.L.), Health Sciences Research (S.D.W., N.T.), and Department of Pathology (J.E.P.), Mayo Clinic, Rochester, MN; Poznan University of Medical Sciences (A.K.-L.), Poland; University of Göttingen (I.M., W.B.), Germany; Medical University of Vienna (J.M.F., H.L.), Austria; and Departments of Neurosciences (C.F.L.), Neurology (C.F.L.), and Clinical and Translational Science (C.F.L.), Mayo Clinic, College of Medicine, Rochester, MN.ORCID 0000-0002-0215-9643
Imke MetzFrom the Department of Neurology (W.O.T., Y.G., L.L.), Health Sciences Research (S.D.W., N.T.), and Department of Pathology (J.E.P.), Mayo Clinic, Rochester, MN; Poznan University of Medical Sciences (A.K.-L.), Poland; University of Göttingen (I.M., W.B.), Germany; Medical University of Vienna (J.M.F., H.L.), Austria; and Departments of Neurosciences (C.F.L.), Neurology (C.F.L.), and Clinical and Translational Science (C.F.L.), Mayo Clinic, College of Medicine, Rochester, MN.ORCID 0000-0002-6571-7630
Josa M FrischerFrom the Department of Neurology (W.O.T., Y.G., L.L.), Health Sciences Research (S.D.W., N.T.), and Department of Pathology (J.E.P.), Mayo Clinic, Rochester, MN; Poznan University of Medical Sciences (A.K.-L.), Poland; University of Göttingen (I.M., W.B.), Germany; Medical University of Vienna (J.M.F., H.L.), Austria; and Departments of Neurosciences (C.F.L.), Neurology (C.F.L.), and Clinical and Translational Science (C.F.L.), Mayo Clinic, College of Medicine, Rochester, MN.ORCID 0000-0002-6638-3476
Hans LassmannFrom the Department of Neurology (W.O.T., Y.G., L.L.), Health Sciences Research (S.D.W., N.T.), and Department of Pathology (J.E.P.), Mayo Clinic, Rochester, MN; Poznan University of Medical Sciences (A.K.-L.), Poland; University of Göttingen (I.M., W.B.), Germany; Medical University of Vienna (J.M.F., H.L.), Austria; and Departments of Neurosciences (C.F.L.), Neurology (C.F.L.), and Clinical and Translational Science (C.F.L.), Mayo Clinic, College of Medicine, Rochester, MN.ORCID 0000-0001-8617-5052
Wolfgang BrückFrom the Department of Neurology (W.O.T., Y.G., L.L.), Health Sciences Research (S.D.W., N.T.), and Department of Pathology (J.E.P.), Mayo Clinic, Rochester, MN; Poznan University of Medical Sciences (A.K.-L.), Poland; University of Göttingen (I.M., W.B.), Germany; Medical University of Vienna (J.M.F., H.L.), Austria; and Departments of Neurosciences (C.F.L.), Neurology (C.F.L.), and Clinical and Translational Science (C.F.L.), Mayo Clinic, College of Medicine, Rochester, MN.ORCID 0000-0002-6881-4479
Linda LinboFrom the Department of Neurology (W.O.T., Y.G., L.L.), Health Sciences Research (S.D.W., N.T.), and Department of Pathology (J.E.P.), Mayo Clinic, Rochester, MN; Poznan University of Medical Sciences (A.K.-L.), Poland; University of Göttingen (I.M., W.B.), Germany; Medical University of Vienna (J.M.F., H.L.), Austria; and Departments of Neurosciences (C.F.L.), Neurology (C.F.L.), and Clinical and Translational Science (C.F.L.), Mayo Clinic, College of Medicine, Rochester, MN.
Claudia F LucchinettiFrom the Department of Neurology (W.O.T., Y.G., L.L.), Health Sciences Research (S.D.W., N.T.), and Department of Pathology (J.E.P.), Mayo Clinic, Rochester, MN; Poznan University of Medical Sciences (A.K.-L.), Poland; University of Göttingen (I.M., W.B.), Germany; Medical University of Vienna (J.M.F., H.L.), Austria; and Departments of Neurosciences (C.F.L.), Neurology (C.F.L.), and Clinical and Translational Science (C.F.L.), Mayo Clinic, College of Medicine, Rochester, MN. clucchinetti@mayo.edu.ORCID 0000-0001-5070-1196
Poznan University of Medical Sciences · PLMayo Clinic in Florida · US
Funding
Mechanisms of Multiple Sclerosis Tissue PathologyR01NS049577 · NINDS · MAYO CLINIC ROCHESTER · PI LUCCHINETTI, CLAUDIA F. · 2006 to 2012
$2.3MNINDS NIH HHS R01 NS049577
Abstract
BACKGROUND AND
objectivesThe goal of this work was to compare clinical characteristics across immunopathologic subtypes of patients with multiple sclerosis.
methodsImmunopathologic subtyping was performed on specimens from 547 patients with biopsy- or autopsy-confirmed CNS demyelination.
resultsThe frequency of immunopathologic subtypes was 23% for pattern I, 56% for pattern II, and 22% for pattern III. Immunopatterns were similar in terms of age at autopsy/biopsy (median age 41 years, range 4-83 years,
conclusionAll 3 immunopatterns can be detected in active lesions, although they are found less frequently later into the disease due to the lower number of active lesions. Pattern III is associated with a more fulminant initial attack than either pattern I or II. Biopsied patients appear to have similar long-term outcomes regardless of their immunopatterns. Progressive disease is less associated with the initial immunopattern and suggests convergence into a final common pathway related to the chronically denuded axon.
Indexed as
Multiple SclerosisPersons with DisabilitiesAdolescentAdultAgedAged, 80 and overAutopsyAxonsChildChild, PreschoolCohort StudiesDisease ProgressionFemaleHumansMiddle AgedYoung Adult
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.